Table 2.

Details of the COVID-19 therapeutic implicated in the adverse event, time to onset of the adverse event, and clinical outcome.

		Patients (N = 46)
COVID-19 therapeutic	Acetaminophen	1 (2.2%)
	Bamlanivimab + etesevimab	1 (2.2%)
	Baricitinib	1 (2.2%)
	Bebtelovimab	5 (10.9%)
	Casirivimab + imdevimab	8 (17.4%)
	Nirmatrelvir + ritonavir	1 (2.2%)
	Remdesivir	22 (47.8%)
	Remdesivir + tocilizumab	2 (4.3%)
	Sotrovimab	5 (10.9%)
Time to symptom onset (hours)	< 12	22 (47.8%)
	13–24	6 (13.0%)
	25–48	6 (13.0%)
	49–72	3 (6.5%)
	> 72	8 (17.4%)
	Unknown	1 (2.2%)
Outcome	Death	0 (0%)
	Permanent disability	0 (0%)
	Life-threatening reaction	4 (8.7%)
	Required intervention to prevent permanent damage	16 (34.8%)
	Presented to Emergency Department	18 (39.1%)
	New hospital admissions (28 patients already hospitalized)	5 (10.9%)
	Transferred to different hospital	2 (4.3%)
	Transferred to Intensive Care Unit	2 (4.3%)